Phenolic a ring requirement for the neuroprotective effects of steroids

Journal of Steroid Biochemistry and Molecular Biology

Volumn 63, Issue 4-6, 1997, Pages 229-235

  Green, Pattie S ^a   Gordon, Katherine ^b   Simpkins, James W ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Apollo Biopharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANDROSTANOLONE; CHOLESTEROL; CORTICOSTERONE; DIETHYLSTILBESTROL; ESTRADIOL; ESTRIOL; ESTROGEN DERIVATIVE; ESTRONE; ETHINYLESTRADIOL; METHYLPREDNISOLONE; PHENOL DERIVATIVE; PREDNISOLONE; PROGESTERONE; STEROID; TESTOSTERONE;

ALZHEIMER DISEASE; ARTICLE; BRAIN PROTECTION; CELL TYPE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG STRUCTURE; ESTROGEN ACTIVITY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; NERVE CELL; NEUROBLASTOMA CELL; STRUCTURE ACTIVITY RELATION;

ESTRADIOL; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; PHENOLS; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0031404546     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00124-6     Document Type: Article

References (39)

1. Paganini-Hill A. and Henderson V. W., Estrogen deficiency and risk of Alzheimer's disease in women. American Journal of Epidemiology 140 (1994) 256-261.
2. Tang M. X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H. and Mayeux R., Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348 (1996) 429-432.
3. Fillit H., Weinreb H., Cholst I., Luine V., McEwen B., Amador R. and Zabriskie J., Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocringology 11 (1986) 337-345.
4. Honjo H., Ogino Y., Naitoh k, Urabe M., Kitawaki J., Yasuda J., Yamamato T., Ishihara S., Okada H. and Yonezawa T.et al., In Vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). Journal Steroid Biochemistry 34 (1989) 521-525.
5. Ohkura T., Issse K., Akazawa K., Hamamoto M., Yaoi Y. and Hagino N., Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1 (1994) 125-130.
6. Paganini-Hill A., Ross R. K. and Henderson B. E., Postmenopausal oestrogen treatment and stroke: a prospective study. British Medical Journal 297 (1988) 519-522.
7. Falkeborn M., Persson I., Terent A., Adami H. O., Lithell H. Bergstrom R., Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch. Internal Medicine 153 (1983) 1201-1209.
8. Finucane F. F., Madans J. H., Bush T. L., Wolf P. H. and Kleinman J. C., Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch. Internal Medicine 153 (1993) 73-79.
9. Boysen G., Nybol J., Appleyard M., Sorensen P. S., Boas J., Somnier F., Jensen G. and Schnohr P., Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke 19 (1988) 1345-1353.
10. Bishop J. and Simpkins J. W., Estradiol treatment increases viability of glioma and neuroblastoma cells in vitro. Molecular and Cellular Neuroscience 5 (1994) 303-308.
11. Simpkins J. W., Singh M. and Bishop J., The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiology of Aging 15 (1994) S195-S197.
12. Green P. S., Bishop J. and Simpkins J. W., 17α-estradiol exerts neuroprotective effects on SK-N-SH cells. Journal of Neuroscience 17 (1997) 511-517.
13. Singh M., Meyer E. M., Millard W. J. and Simpkins J. W., Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Research 644 (1994) 305-312.
14. Singh M., Meyer E. M. and Simpkins J. W., The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology 136 (1995) 2320-2324.
15. Green P. S., Gridley K. E. and Simpkins J. W., Estradiol protects against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neuroscience Letters 218 (1996) 165-168.
16. Singer C. A., Strickland T. M., Rogers K. L. and Dorsa D. M., Estrogen protects primary cortical neurons from glutamate neurotoxicity. Neuroscience Letters 212 (1996) 13-16.
17. Black L. and Berenbaum M. C., Factors affecting the dye exclusion test for cell viability. Experimental Cell Research 35 (1964) 9-13.
18. Huggins C., Jensen E. V. and Cleveland A. S., Chemical structure of steroids in relation to promotion of growth of vagina and uterus of the hypophysectomized rat. Journal Experimental Medicine 100 (1954) 225-231.
19. Koreman S. G., Comparative binding affinity of estrogens and its relationship to estrogen potency. Steroids 13 (1969) 163-169.
20. Martucci C. P. and Fishman J., Impact of continuously administered catechol estrogen on uterine growth and luteinizing hormone secretion. Endocrinology 105 (1979) 1288-1292.
21. Clark J. H., Williams M., Upchurch S., Eriksson H., Helton E. Markaverich B. M., Effects of estradiol-17α on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites and uterine growth. Journal Steroid Biochemistry 16 (1982) 323-328.
22. Clark J. H. and Markaverich B. M., The agonistic and antagonist effects of short acting estrogen: a review. Pharmacology and Therapeutics 21 (1983) 429-453.
23. Papendorp J. T., Schatz R. W., Soto A. M. and Sonnenschein C., On the role on 17α-estradiol and 17β-estradiol in the proliferation of MCF7 and T47D-A11 human breast tumor cells. Journal Cell Physiology 125 (1985) 591-595.
24. Behl C., Widmann M., Trapp T. and Holsboer F., 17β-estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochemical and Biophysical. Research Communication 216(1995)473-482.
25. Behl C., Skutella T., Lezoualc'h F., Post A., Widmann M., Newton C. J. and Holsboer F., Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Molecular Pharmacology 51 (1997) 535-541.
26. Shi J., Zhang Y. Q. and Simpkins J. W., Effects of 17β-estradiol on glucose transporter 1 expression and endothelial cell survival following focal ischemia in rats. Experimental Brain Research in press (1997).
27. Niki E., Antioxidants in relation to lipid peroxidation. Chemistry and Physics of Lipids 44 (1987) 227-253.
28. Nakano A., Sugioka K., Naito I., Takekoshi S. and Niki E., Novel and potent biological antioxidants on membrane phospholipid peroxidation: 2-hydroxy estrone and 2-hydroxy estradiol. Biochemical and Biophysical Research Communication 142 (1987) 919-924.
29. Mukai K., Daifuku K., Yokoyama S. and Nakano M., Stopped-flow investigation of antioxidant activity of estrogens in solution. Biochimicia et Biophysica Acta 1035 (1990) 348-352.
30. Hall E. D., Pazara K. E. and Linseman K. L., Sex differences in postischemic neuronal necrosis in gerbils. Journal Cerebral Blood Flow and Metabolism 11 (1991) 292-298.
31. Goodman Y., Bruce A. J., Cheng B. and Mattson M. P., Estrogens attenuate and corticosterone exacerbates excitotoxi-city, oxidative injury, and amyloidβ-peptide toxicity in hippocampal neurons. Journal of Neurochemistry 66 (1996) 1836-1844.
32. Tappel A. L., Lipid peroxidation damage to cell components. Federation Proceedings 32 (1973) 1870-1874.
33. Flamm E. S., Demopoulos H. B., Seligman M. L., Poser R. G. Ransohoff J., Free radicals in cerebral ischemia. Stroke 9 (1978) 445-447.
34. Yoshida S., Abe K., Busto R., Watson B. D., Kogure K. and Ginsberg M. D., Influence of transient ischemia on lipid-soluble antioxidants, free fatty acids and energy metabolites in rat brain. Brain Research 245 (1982) 307-316.
35. Braughler J. M. and Hall E. D., Central nervous system trauma and stroke. Biochemical considerations, oxygen radical formation and lipid peroxidation. Free Radicals in Biology and Medicine 6 (1989) 289-301.
36. Carney J. M., Starke-Reed P. E., Oliver C. N., Landum R. W., Cheng M. S., Wu J. F. and Floyd R. A., Reversal of agerelated increase in brain protein oxidation, decrease in enzyme activity and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-α-phenylnitrolyl. Proceedings of the National Academy of Sciences USA 88(1991) 3633-3636.
37. Smith C. D., Carney J. M., Starke-Reed P. E., Oliver C. N., Stadtman E. R., Floyd R. A. and Markesbery W. R., Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proceedings National Academy of Sciences USA 88 (1991) 10540-10543.
38. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F., Floyd R. A. and Butterfield D. A., A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proceedings of the National Academy of Sciences USA 91 (1994) 3270-3274.
39. Hall E. D., The neuroprotective pharmacology of methylprednisolone. Journal of Neurosurgery 76 (1992) 13-22.